Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Annals of Oncology

Topics

Medicine

Cancer Oncology

Immunology

Internal Medicine

Urology

Show all topics

DOI

10.1093/annonc/mdx235

License

CC-BY-NC

Other Formats

PDF